FRANKLIN, Mass., March 22, 2011 /PRNewswire/ — Echo
Therapeutics, Inc. (OTC Bulletin Board:
ECTE), a company developing the Symphony™ tCGM System as
a non-invasive, wireless, transdermal continuous glucose monitoring
(tCGM) system and the Prelude™ SkinPrep System for
transdermal drug delivery, today announced that John Garibotto and
Kenneth Gary, who collectively have nearly fifty years of medical
device and diagnostics experience, have joined Echo Therapeutics’
senior management team as part of the company’s plan to accelerate
the development of the Symphony System and other new products
contemplated in the Company’s growth strategy.
John Garibotto joins as Vice President of Operations. In this
newly created position, he will oversee Echo’s product development,
engineering, manufacturing, regulatory and quality functions.
Kenneth Gary joins as Vice President of Research, clinical and
new products. He will oversee new product research activities and
the design and execution of supporting clinical trials.
“John’s and Ken’s significant experience in complete product
development from ideation to final FDA approval of medical devices
and diagnostics will ensure the aggressive product development and
successful clinical validation of our Symphony tCGM System,” said
Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics. “We
are extremely pleased to have such highly valuable, successful and
seasoned industry veterans join the Company as we move toward our
final goal of FDA marketing clearance of Symphony. We plan to
leverage their deep domain expertise as Echo looks to broaden its
product pipeline over the coming year.”
Mr. Garibotto has 23 years of medical device experience with a
proven track record of building and leading large
multi-disciplinary teams through ideation, regulatory approval,
commercialization and mass m
‘/>”/>
